Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer

Martin S. Denzel, Lionel W. Hebbard, Gregory Shostak, Lawrence Shapiro, Robert Cardiff, Barbara Ranscht

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Purpose: High levels of the fat-secreted cytokine adiponectin (APN) are present in the circulation of healthy people, whereas low levels correlate with an increased incidence of breast cancer in women. The current study experimentally probes the physiologic functions of APN in mammary cancer in a newly generated genetic mouse model. Experimental Design: We established an APN null mouse model of mammary cancer by introducing the polyoma virus middle T (PyV-mT) oncogene expressed from mouse mammary tumor virus (MMTV) regulatory elements into APN null mice. MMTV-PyV-mT -induced tumors resemble ErbB2-amplified human breast cancers. We monitored tumor onset, kinetics, and animal survival, and analyzed vascular coverage, apoptosis, and hypoxia in sections from the primary tumors. Metastatic spreading was evaluated by analyses of the lungs. Results: APN prominently localized to the vasculature in human and mouse mammary tumors. In APN null mice, MMTV-PyV-mT-induced tumors appeared with delayed onset and exhibited reduced growth rates. Affected animals survived control tumorbearing mice by an average of 21 days. Pathologic analyses revealed reduced vascularization of APN null tumors along with increased hypoxia and apoptosis. At the experimental end point, APN null transgenic mice showed increased frequency of pulmonary metastases. Conclusion: The current work identifies a proangiogenic contribution of APN in mammary cancer that, in turn, affects tumor progression. APN interactions with vascular receptors may be useful targets for developing therapies aimed at controlling tumor vascularization in cancer patients.

Original languageEnglish (US)
Pages (from-to)3256-3264
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number10
DOIs
StatePublished - May 15 2009

Fingerprint

Mouse mammary tumor virus
Polyomavirus
Adiponectin
Breast Neoplasms
Neoplasms
Blood Vessels
Apoptosis
Lung
Hypoadiponectinemia
Genetic Models
Oncogenes
Transgenic Mice
Research Design
Fats
Cytokines
Neoplasm Metastasis
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. / Denzel, Martin S.; Hebbard, Lionel W.; Shostak, Gregory; Shapiro, Lawrence; Cardiff, Robert; Ranscht, Barbara.

In: Clinical Cancer Research, Vol. 15, No. 10, 15.05.2009, p. 3256-3264.

Research output: Contribution to journalArticle

Denzel, Martin S. ; Hebbard, Lionel W. ; Shostak, Gregory ; Shapiro, Lawrence ; Cardiff, Robert ; Ranscht, Barbara. / Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 10. pp. 3256-3264.
@article{8b04d5e1b1bf4a73b7eb138b090d397f,
title = "Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer",
abstract = "Purpose: High levels of the fat-secreted cytokine adiponectin (APN) are present in the circulation of healthy people, whereas low levels correlate with an increased incidence of breast cancer in women. The current study experimentally probes the physiologic functions of APN in mammary cancer in a newly generated genetic mouse model. Experimental Design: We established an APN null mouse model of mammary cancer by introducing the polyoma virus middle T (PyV-mT) oncogene expressed from mouse mammary tumor virus (MMTV) regulatory elements into APN null mice. MMTV-PyV-mT -induced tumors resemble ErbB2-amplified human breast cancers. We monitored tumor onset, kinetics, and animal survival, and analyzed vascular coverage, apoptosis, and hypoxia in sections from the primary tumors. Metastatic spreading was evaluated by analyses of the lungs. Results: APN prominently localized to the vasculature in human and mouse mammary tumors. In APN null mice, MMTV-PyV-mT-induced tumors appeared with delayed onset and exhibited reduced growth rates. Affected animals survived control tumorbearing mice by an average of 21 days. Pathologic analyses revealed reduced vascularization of APN null tumors along with increased hypoxia and apoptosis. At the experimental end point, APN null transgenic mice showed increased frequency of pulmonary metastases. Conclusion: The current work identifies a proangiogenic contribution of APN in mammary cancer that, in turn, affects tumor progression. APN interactions with vascular receptors may be useful targets for developing therapies aimed at controlling tumor vascularization in cancer patients.",
author = "Denzel, {Martin S.} and Hebbard, {Lionel W.} and Gregory Shostak and Lawrence Shapiro and Robert Cardiff and Barbara Ranscht",
year = "2009",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-08-2661",
language = "English (US)",
volume = "15",
pages = "3256--3264",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer

AU - Denzel, Martin S.

AU - Hebbard, Lionel W.

AU - Shostak, Gregory

AU - Shapiro, Lawrence

AU - Cardiff, Robert

AU - Ranscht, Barbara

PY - 2009/5/15

Y1 - 2009/5/15

N2 - Purpose: High levels of the fat-secreted cytokine adiponectin (APN) are present in the circulation of healthy people, whereas low levels correlate with an increased incidence of breast cancer in women. The current study experimentally probes the physiologic functions of APN in mammary cancer in a newly generated genetic mouse model. Experimental Design: We established an APN null mouse model of mammary cancer by introducing the polyoma virus middle T (PyV-mT) oncogene expressed from mouse mammary tumor virus (MMTV) regulatory elements into APN null mice. MMTV-PyV-mT -induced tumors resemble ErbB2-amplified human breast cancers. We monitored tumor onset, kinetics, and animal survival, and analyzed vascular coverage, apoptosis, and hypoxia in sections from the primary tumors. Metastatic spreading was evaluated by analyses of the lungs. Results: APN prominently localized to the vasculature in human and mouse mammary tumors. In APN null mice, MMTV-PyV-mT-induced tumors appeared with delayed onset and exhibited reduced growth rates. Affected animals survived control tumorbearing mice by an average of 21 days. Pathologic analyses revealed reduced vascularization of APN null tumors along with increased hypoxia and apoptosis. At the experimental end point, APN null transgenic mice showed increased frequency of pulmonary metastases. Conclusion: The current work identifies a proangiogenic contribution of APN in mammary cancer that, in turn, affects tumor progression. APN interactions with vascular receptors may be useful targets for developing therapies aimed at controlling tumor vascularization in cancer patients.

AB - Purpose: High levels of the fat-secreted cytokine adiponectin (APN) are present in the circulation of healthy people, whereas low levels correlate with an increased incidence of breast cancer in women. The current study experimentally probes the physiologic functions of APN in mammary cancer in a newly generated genetic mouse model. Experimental Design: We established an APN null mouse model of mammary cancer by introducing the polyoma virus middle T (PyV-mT) oncogene expressed from mouse mammary tumor virus (MMTV) regulatory elements into APN null mice. MMTV-PyV-mT -induced tumors resemble ErbB2-amplified human breast cancers. We monitored tumor onset, kinetics, and animal survival, and analyzed vascular coverage, apoptosis, and hypoxia in sections from the primary tumors. Metastatic spreading was evaluated by analyses of the lungs. Results: APN prominently localized to the vasculature in human and mouse mammary tumors. In APN null mice, MMTV-PyV-mT-induced tumors appeared with delayed onset and exhibited reduced growth rates. Affected animals survived control tumorbearing mice by an average of 21 days. Pathologic analyses revealed reduced vascularization of APN null tumors along with increased hypoxia and apoptosis. At the experimental end point, APN null transgenic mice showed increased frequency of pulmonary metastases. Conclusion: The current work identifies a proangiogenic contribution of APN in mammary cancer that, in turn, affects tumor progression. APN interactions with vascular receptors may be useful targets for developing therapies aimed at controlling tumor vascularization in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=66149179123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149179123&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2661

DO - 10.1158/1078-0432.CCR-08-2661

M3 - Article

C2 - 19447866

AN - SCOPUS:66149179123

VL - 15

SP - 3256

EP - 3264

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -